BioSpace News Archive

Neural Therapeutics Inc. (“Neural” or the “Company”), an ethnobotanical drug-discovery and development company, is pleased to announce that it has closed the first tranche of the private placement (“Private Placement”) for gross proceeds of $293,346.42 and completed debt settlement of approximately $327,845.49 (“Debt Settlement”).

Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announces changes to its Board of Directors following the Company’s recent 2023 Annual Meeting of Stockholders.

American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRD) (“Aires” or the “Company”), a company focused on scientifically-proven EMF modulation technology, announces that holders of secured convertible debentures have converted an aggregate of $1,885,188 of principal and accrued and unpaid interest

RaySearch Laboratories AB is proud to announce the continued commitment with Mevion Medical Systems, the leading global provider of compact proton therapy solutions, to develop new proton therapy solutions in support of current and emerging technologies.

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced results from a post-hoc analysis from the Phase 3 SPOTLIGHT trial (NCT04186845) that investigated the use of POSLUMA® (flotufolastat F 18) PET in suspected biochemical recurrence of prostate cancer.

Myeloid Therapeutics, Inc., a clinical stage mRNA-immunotherapy company, announced that it will participate in the following investor conferences.

Gamida Cell Ltd . (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Abbey Jenkins, President and Chief Executive Officer, will present its corporate highlights at the annual Cell & Gene Meeting on the Mesa to be held October 10-12 in Carlsbad, California, and livestreamed globally.

Evecxia Therapeutics, Inc., the leader in serotonin synthesis amplification to treat brain disorders, today announced the absence of toxicity findings associated with the co-administration of EVX-101 in conjunction with the first-line antidepressant fluoxetine in nonclinical GLP toxicology studies.

Boundless Bio today announced the appointment of two new members to its Board of Directors and the establishment of its Clinical Advisory Board.

Horizon Therapeutics plc Announces New UPLIZNA ® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023.